A co-ordinated, evidence-based approach to treatments following cardiac arrest can have a significant impact on outcome. In comatose survivors of cardiac arrest, therapeutic hypothermia (temp 32-34°C) should be induced as soon as possible and maintained for 12-24 hours before controlled rewarming. Cardiac impairment is usually transient and responds to fluids and vasopressors/inotropes. Aim for a mean arterial blood pressure to achieve adequate end organ perfusion. Patients with a suspected cardiac cause of their arrest should be considered for angiography with or without percutaneous transluminal coronary angioplasty (PTCA). Hyperglycaemia should be treated with insulin. Controlled ventilation should aim for oxygen saturations of 94-96% and normocapnia. Prognostic tests are unreliable initially and should be deferred until at least 72 hours following return of normothermia.
Incidence and outcome from cardiac arrests
It is estimated that from approximately 50,000 treated cardiac arrests each year in the UK, around 6,350 (12.7%) will be admitted to an intensive care unit (ICU). Data from the Intensive Care National Audit and Research Centre Case Mix Programme Database (ICNARC CMPD) recorded that patients admitted for postresuscitation care made up 5.8% of all admissions. Of a total of 24,132 cardiac arrest patients admitted to intensive care, 42.9% were discharged alive from ICU and 28.6% survived to hospital discharge. 1 Outcome of out-of-hospital cardiac arrest (OHCA) survivors has remained poor and can vary considerably between different hospitals.
There has been increasing recognition that the care of patients after return of spontaneous circulation (ROSC) has been achieved plays an important role in determining patient outcome. This is reflected by the addition of postresuscitation care as a link to the 'chain of survival' (Figure 1) . 2, 3 The International Liaison Committee for Resuscitation 4 and the Intensive Care Society 5 have produced guidelines and clinical standards for the management of patients during the postresuscitation phase of care. This article will outline current thinking in relation to pathophysiology, treatment and prognostication of postresuscitation syndrome.
Postresuscitation syndrome
The concept of a postresuscitation syndrome was first described by Negovsky, a Russian pathophysiolologist in 1972. High mortality seen in cardiac arrest is a result of the pathology that caused the cardiac arrest compounded by global ischaemia and subsequent reperfusion injury. Current theories describe the release of pro-inflammatory cytokines (IL-1β, IL-8, TNFα) leading to a systemic inflammatory response and 'sepsis-like syndrome' following resuscitation. 6 Clinically, the postresuscitation syndrome presents with neurological dysfunction, cardiovascular instability and multi-organ dysfunction.
Post-cardiac arrest brain injury
The brain is uniquely susceptible to ischaemia and reperfusion injury. Brain injury is the result of complex interactions of excitotoxicity, disrupted calcium homeostasis, formation of free radicals, protease cascades and combination of apoptosis and neuronal necrosis. Susceptible parts of the brain include the hippocampus, cortex, cerebellum, corpus striatum and thalamus. Cerebral autoregulation is disrupted post-cardiac arrest, with cerebral perfusion varying with cerebral perfusion pressure rather than neuronal activity. 7 In 2008, Lemiale et al studied changes in cerebral blood flow (CBF) and oxygen extraction (CEO 2 ) in 18 survivors of out-of-hospital cardiac arrests. They found that cerebral perfusion, as indicated by transcranial doppler velocities, was severely impaired not just for initial phases but for up to 72 hours postresuscitation. Both CBF and CEO 2 improved in survivors, whereas in nonsurvivors only CBF improved while CEO 2 remained persistently low. 8 There is some evidence to suggest that hyperoxia during the reperfusion stages can lead to increased free radical formation and mitochondrial oxidative injury, thereby exacerbating neuronal injury. 9
Post-cardiac arrest myocardial dysfunction
Heart rate and blood pressure can be labile immediately post ROSC and a normal or elevated reading can be a result of catecholamine release and can mask underlying myocardial dysfunction. Post-cardiac arrest myocardial dysfunction is a result of myocardial stunning and can be seen without evidence of reduced coronary blood flow or infarction. Increased levels of myocardial inflammatory cytokines (IL-8) and inducible nitric oxide synthase (iNOS) have been implicated in the pathogenesis of myocardial dysfunction. 10 A dose-response relationship between the duration of hypoxia and myocardial dysfunction has been demonstrated in animals. 11 Myocardial dysfunction is manifested by initial tachycardia and elevated left ventricular end diastolic pressure, followed by hypotension (MAP <75 mm Hg) and low cardiac output (cardiac index <2.2 L/min/m 2 ) in six hours. 12 However, dysfunction is transient and full recovery can be expected with cardiac index values improving within 24 hours and returning to normal in most patients by 72-hours post arrest, although sustained depression of myocardial function with residual dysfunction can be seen for several weeks or months. 13
Systemic ischaemia and reperfusion injury
During cardiac arrest, the delivery of oxygen and metabolic substrates is severely impaired. Systemic ischaemic-reperfusion response is similar to sepsis and leads to intravascular volume depletion, impaired vasoregulation, impaired oxygen delivery and utilisation and increased susceptibility to infection. 6 Significant oxygen debt leads to endothelial activation and systemic inflammation. 14 An increased level of intercellular and vascular adhesion molecules suggests leucocyte activation or endothelial injury. Endotoxin intolerance and hyporesponsiveness in leucocytes is also seen. Activation of coagulation pathways leads to widespread fibrin formation and microthromboses. Production of anticoagulant factors such as antithrombin, protein C and protein S is decreased. 15 Suppression of adrenal function is also seen in post-cardiac arrest patients. A low basal cortisol level was recorded between 6-36 hours post-arrest in patients who died from early refractory shock. 16 
Clinical interventions during postresuscitation care
The 'chain of survival' describes a series of inter-related steps which can improve outcomes following cardiac arrest. 17 In 2005, the chain was updated to include postresuscitation care in response to growing evidence that treatments in this phase have a significant influence on overall outcomes (Figure 1 ). The concept of care bundles, popularised by the 'Surviving Sepsis' campaign has been applied to the management of postresuscitation care. A combination of protocol-guided therapeutic hypothermia, early revascularisation and glycaemic control have been associated with improved process and clinical outcomes in this population of patients. 18 Figure 2 shows the postresuscitation care bundle in use at our institution.
Therapeutic hypothermia
A number of studies have shown that hyperthermia following return of spontaneous circulation is associated with poor outcomes. A temperature >39°C in the first 72 hours has been linked to the development of brain death. 19 Zeiner et al found an increased risk of unfavourable outcome with every degree increase in temperature above 37°C (OR 2.3, 95% CI 1.2-4.1). 20 A retrospective study from Norway compared factors affecting outcome and also found that a temperature >37.8°C was associated with increased in-hospital mortality (OR 2.7, 95% CI 1.2-6.3). 21 Therapeutic hypothermia was first used to treat cardiac arrest survivors in the 1950s. 22 The technique fell out of favour due to inconsistencies in outcomes and difficulties in achieving and controlling temperature. The first of a new era of clinical studies to demonstrate the beneficial effects of mild to moderate therapeutic hypothermia was the European 'Hypothermia after Cardiac Arrest' study. 23 This multicentre, randomised controlled trial allocated patients that had sustained an out-of-hospital cardiac arrest with ventricular fibrillation (VF) to receive therapeutic hypothermia or standard care. Patients in the intervention arm underwent surface cooling, aiming for a core temperature of 32-34°C for 12-24 hours after return of spontaneous circulation. Fifty-five percent of patients in the hypothermia arm had a favourable neurological outcome compared to 39% in the normothermia group (RR 1.40; 95% CI 1.08 to 1.81). Mortality at six months was also reduced to 41% in the hypothermia group compared to 55% in the normothermia group. 23 A recent Cochrane review combined these data with data from four other randomised/pseudo-randomised controlled trials to conclude that conventional cooling methods to induce mild therapeutic hypothermia improve survival and neurological outcome after cardiac arrest. 24 There was insufficient evidence for patients with in-hospital cardiac arrest, asystole, pulseless electrical activity (PEA) and non-cardiac causes of arrest to make firm inferences. However, as global cerebral ischaemic insults are similar there is no reason why therapeutic hypothermia should not be as effective in these patients. 4 Inducing therapeutic hypothermia can be broken down into three phases -induction, maintenance and re-warming. The systematic review published in JICS recommended that hypothermia be induced by intravenous infusion of 30 mL/kg ice-cold (4°C) crystalloid over 30 minutes. 25 Methods for maintaining the temperature in the target range was best achieved by either automated external cooling blanket or endovascular catheters. While less expensive techniques such as the use of ice-packs can be effective, they are usually more time-consuming and can lead to greater fluctuations in temperature. Current guidelines recommend that hypothermia is induced as soon as possible after cardiac arrest and that a core temperature of 32-34°C is maintained for at least 12-24 hours. Rewarming should be controlled to ensure the rewarming rate does not exceed 0.25-0.5°C per hour. 26 Hyperthermia during rewarming should be aggressively treated.
Therapeutic hypothermia can be associated with side effects such as cardiovascular instability, coagulopathy, increased risk of infection, hyperglycaemia, and electrolyte abnormalities such as hypophosphataemia and hypomagnesaemia. 27
Optimising physiology Haemodynamic optimisation
Early goal-directed therapy has been used in patients with sepsis and has been suggested to be equally effective in the ischaemia-reperfusion response seen after cardiac arrest. Mean arterial blood pressure (MABP) during the first two hours post- 
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Prognostician
The following are predictors of poor outcome in patients not managed with therapeutic hypothermia. Evidence suggests that these clinical markers are less reliable in patients who have been cooled. If therapeutic hypothermia has been used, delay tests until at least 72 hours after normothermia has been restored.
• Myoclonus status epilepticus during first 24 hours after ROSC.
• Absent pupillary responses or corneal reflexes, 24-72 hours after ROSC.
• Extensor or absent motor responses 72 hours after ROSC.
Neither the nature of the arrest (eg downtime) nor the presence of sporadic seizures should not be used to predict prognosis in isolation.
Brain imaging (CT/MRI) lacks sufficient specificity for routine use as a tool for predicting outcome. However, a CT scan may identify a structural brain injury (eg intracerebral bleed/infarct) that may adversely affect outcome.
Findings on EEG lack sufficient precision for prognostication. However they may have a role in confirming the presence of seizure activity. Status epilepticus and status myoclonus are associated with poor outcomes.
Communication
• Ensure early discussion with relatives
• Give guarded prognosis regarding outcome (ICNARC data suggest 43% will survive to ICU discharge, but only 29% survive to hospital discharge)
• It is not possible in the early days to determine the likelihood of neurological recovery. The picture will become clearer over the following days.
Figure 2
Resuscitation care bundle.
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arrest is positively correlated to neurological outcome. Good outcomes have been demonstrated with low MABP of 65-75 mm Hg to high MABP of 90-100 mm Hg. 28 A target central venous pressure of 8-12 mm Hg has been used 18 but its measurement should be used with caution as persistent pathology, such as pulmonary embolism, right-sided acute myocardial infarction or tension pneumothorax, can cause inaccurate CVP readings. Optimal mixed venous saturation has not been defined. Venous hyperoxia, where poor oxygen utilisation leads to an elevated SvO 2 despite adequate oxygen delivery, makes SvO 2 an unreliable indicator of oxygen delivery. Due to the heterogeneous causes of cardiac arrests, there has been no consensus to date in the optimal parameters to be achieved after cardiac arrest. A systematic review by Jones et al in 2008 concluded that there are currently no clinical trials that have examined goal-directed optimisation and no evidence for which is the best strategy. 28 In the absence of definitive evidence for specific haemodynamic parameters, targeting surrogates of oxygen delivery such as decreasing serum lactate or urine output of >1 mL/kg/h may be useful.
Glucose control
Hyperglycaemia is common after cardiac arrest and is associated with a worse outcome. Early enthusiasm for tight glycaemic control using insulin to maintain blood glucose between 4.4-6.1 mmol/L has not been sustained. Results from the initial study, which demonstrated tight glycaemic control reduces mortality in critically ill surgical patients, 29 have not been reproduced in later trials. 30 Indeed in the NICE-SUGAR study, mortality was increased in the group allocated to tight glycaemic control. Studies in cardiac arrest patients are limited. A small, randomised controlled study in cardiac arrest survivors failed to demonstrate any improvement in mortality or other outcomes with a tight glycaemic control regimen (blood glucose 4-6 mmol/L) versus moderate glycaemic control (blood glucose 6-8 mmol/L). However, there was a significant risk of hypoglycaemia in the tight glycaemic control arm (18%, versus 2% in the control arm). 31 The consensus of evidence at present is that the target range for blood sugar after cardiac arrest should be somewhere between 8-10 mmol/L.
Revascularisation
Percutaneous transluminal coronary intervention
Postmortem studies have reported an incidence of 78% of coronary artery disease in cardiac arrest patients 32 with up to 64% having acute changes in coronary plaque morphology. 33 Coronary angiography followed by mechanical revascularisation has led to survival benefit in post-cardiac arrest patients including those with significant shock. 34, 35 The combination of cooling and early percutaneous coronary intervention (PCI) has reportedly improved outcome, with a 75% survival-to-discharge rate in cooling plus PCI, compared to 44% in the PCI-only group. 36
Anti-arrhythmic therapy
Cardiac arrhythmias are common after cardiac arrests and can be caused by focal cardiac ischaemia. Plasma potassium should be kept between 4.0-4.5 mmol/L. Consistent improvement in long-term outcomes has not been achieved when prophylactic anti-arrhythmics are given to cardiac arrest survivors. In initial survivors of cardiac arrest due to lethal arrhythmia, the use of an implantable cardioverter defibrillator is associated with increased survival compared to drug therapy. 37
Anticonvulsant therapy
Seizures and/or myoclonus occur in up to 40% of cardiac arrest survivors and increase cerebral metabolism. 38, 39 Prolonged seizure activity can cause cerebral injury and should be treated promptly with benzodiazepines, phenytoin, sodium valproate, barbiturates or propofol. Status myoclonus is often refractory to standard anticonvulsant medication although some success has been observed with low doses of intravenous propofol. 40
Prognostication
The ability to predict the likely neurological outcome and prognosis of a cardiac arrest survivor following admission to critical care is important. Up to two thirds of OHCA patients die in intensive care as a consequence of poor neurological recovery and a quarter of those following in-hospital arrest. A variety of clinical, electrophysiological and laboratory tests have been evaluated as predictors of outcome from 24 hours after cardiac arrest, but few centres have the facilities to routinely perform many of the electrophysiological or laboratory tests. Reliable tests predicting outcome would help target aggressive treatment to patients likely to have a good outcome, while allowing early palliation and withdrawal of life-sustaining treatments in cases where continuing care is futile. A major limitation of many of the published studies is that the knowledge of the test outcome often affects the decision-making process about withdrawal and has the risk of becoming a self-fulfilling prophecy.
Preadmission factors
Patient factors suggesting poor outcome include increasing age, previous history of diabetes, heart failure. 41, 42 Good quality CPR is important and the level of consciousness, presence of cardiogenic shock and sinus rhythm have a significant impact on survival. 41 In relation to the cardiac arrest episode, the initial rhythm, whether the arrest was witnessed, whether bystander CPR was attempted, time to first defibrillation and duration of the arrest are the most important factors. 43 Unfortunately, none of these characteristics has sufficient predictive power to be used for individual patient treatment decisions.
Clinical examination
The presence of myoclonus status epilepticus within the first 24 hours is associated with poor outcome. Absent pupillary and corneal reflexes within days 1-3 and absent or extensor motor responses after day three accurately predict poor neurological outcome in patients following cardiac arrest. 44 However, the presence of these responses do not reliably predict good neurological outcome.
Electrophysiological tests
Electroencephalograms (EEG) have been evaluated as a prognostic tool post cardiac arrest but many studies suffer from different classification systems and varying intervals from CPR attempt. Burst suppression or generalised epileptiform discharges on EEG predict poor outcomes but have insufficient prognostic accuracy. 44 Somatosensory evoked potentials (SSEPs) are less influenced by drugs and metabolic derangements and are found to be more accurate than EEG in prognostication. The evidence suggests that bilateral absence of the N20 component of the SSEP with median nerve stimulation, recorded from cervical cord and brachial plexus level on days 1 to 3 or later after CPR, can accurately predict a poor outcome. [44] [45] [46] However, it is a technique that requires substantial expertise and is not currently widely available.
Neuroimaging
Computed tomography is frequently performed to exclude primary brain injury that may have caused cardiac arrest. Although cerebral oedema is a common finding around day three after cardiac arrest, this finding lacks sufficient precision to be regarded as a valuable prognostic tool. Magnetic resonance imaging (MRI) is showing promise as an early tool for predicting outcome in this patient population. However, further studies are required to fully evaluate its performance as a prognostic tool. 44
Biochemical markers
Neuron-specific enolase (NSE) is the most abundant form of the glycolytic enzyme enolase found in adult neurons and serves as a growth factor in neurons. NSE is a recognised marker of ischaemic brain damage. 47 Higher NSE levels (median 44.24 ng/mL, range 8.1-370) were found in post cardiac arrest patients with worse outcome than those with better outcome (25.26 ng/mL, range 9.28-55.41; p=0.034). 48 Grubb et al found a cut-off of >71.0 µg/L between 24-48 hours after ROSC was needed to achieve false positive rate (FPR) of 0% (95% CI 0%-43%) 49 whereas a study by Zandbergen used the cut-off of >33 µg/L between 24-72 hours after ROSC to achieve FPR of 0% (95% CI 0%-3%). 45 S100β is a calcium binding protein from astrocytes and Schwann cells. Studies have found S100β to be a marker with high specificity but low sensitivity. In one study, cut-off values of >1.2 µg/L in blood drawn between 24-48 hours after ROSC achieved a FPR of 0% (95%CI 05-14%) with a sensitivity of 45%. 49 Variability in the timings and type of assays used mean there is a lack of consistency in the cut-off values used for prognostication. This, combined with the lack of widespread availability of these tests leave this technology as largely experimental.
The OHCA score developed by Adrie et al has five parameters: plasma lactate and creatinine levels, initial rhythm, no-flow and low-flow interval. OHCA score performs well when compared to other scoring system but suffers from the pitfalls that it is hard to measure no-flow and low flow intervals precisely. It remains to be validated across different health systems. 43
Impact of therapeutic hypothermia
The majority of studies assessing clinical, physiological and imaging tests for prognostication after cardiac arrest were performed prior to the widespread adoption of therapeutic hypothermia. It is increasingly recognised that the performance of prognostic tests are influenced by the use of therapeutic hypothermia. In one study where the majority (62%) of patients were treated with therapeutic hypothermia, 5/49 (10%) had absent motor responses at 72 hours but survived. Despite absent pupillary responses at 72 hours, 22/36 (61%) survived. Only absent corneal reflexes at 72 hours reliably predicted death. 50 The performance of neuro-enzymes is also influenced by hypothermia. Somatosensory evoked potentials appear to be less affected by hypothermia. Most authorities in this field now recognise the need to delay prognostic testing until at least 72 hours after normothermia has been restored.
Summary
The development of post-cardiac arrest syndrome is common in initial survivors of cardiac arrest. Postresuscitation care has rightly become part of the chain of survival given the growing evidence demonstrating that the care received during this phase of resuscitation has a significant influence on final patient outcomes. The development of postresuscitation care bundles which include protocols for therapeutic hypothermia, primary percutaneous coronary intervention, control of blood sugar and a systematic approach to prognostication, is likely to play a significant part in improving process and patientfocused outcomes.
